TELA BIO, INC. (TELA) News
Filter TELA News Items
TELA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TELA News Highlights
- For TELA, its 30 day story count is now at 2.
- Over the past 10 days, the trend for TELA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about TELA are BIO, DEC and PR.
Latest TELA News From Around the Web
Below are the latest news stories about TELA BIO INC that investors may wish to consider to help them evaluate TELA as an investment opportunity.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Dec. 15, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,175 shares of its common stock |
TELA Bio to Take Part in Connecting the DotsMALVERN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, announced today that it took part in a segment in Connecting the Dots, a series of branded films presented by MedTech Europe and including a film produced for them by BBC StoryWorks Commercial Pr |
TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare ConferenceMALVERN, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in Piper Sandler’s 35th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 35th Annual Healthcare Confere |
TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call TranscriptTELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good day and thank you for standing by, and welcome to the TELA Bio Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today’s conference call is being recorded. I […] |
TELA Bio Reports Third Quarter 2023 Financial ResultsMALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Revenue of $15.1 million in the third quarter, representing growth of 35% over the third quarter o |
TELA Bio to Announce Third Quarter 2023 Financial ResultsMALVERN, Pa., Oct. 26, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will report third quarter 2023 financial results on Thursday, November 9, 2023. TELA Bio’s management will host a conference call and webcast at 4:30 |
TELA Bio to Participate in the Gilmartin Group Emerging Growth Company ShowcaseMALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in the Gilmartin Group Emerging Growth Company Showcase. TELA’s management is scheduled to present at the Gilmartin Group Emerging Growth Compan |
TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive SurgeryNew addition expands reconstruction options for surgeons and patientsMALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced the launch of their OviTex PRS Long-Term Resorbable product. OviTex PRS Long-Term Resorbable is intended for i |
TELA Bio, Inc. (NASDAQ:TELA) Q2 2023 Earnings Call TranscriptTELA Bio, Inc. (NASDAQ:TELA) Q2 2023 Earnings Call Transcript August 9, 2023 TELA Bio, Inc. beats earnings expectations. Reported EPS is $-0.46, expectations were $-0.58. Operator: Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] […] |
Q2 2023 TELA Bio Inc Earnings CallQ2 2023 TELA Bio Inc Earnings Call |